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ABSTRACT: 47
We hypothesized that the cardioselective β 1 -adrenoreceptor antagonist esmolol would improve 48 maximal apnea duration in elite breath hold divers. In elite national level divers (n=9), maximal 49 apneas were performed in a randomized and counterbalanced order while receiving either i.v. 50 esmolol (150μg ⋅ kg -1 ⋅ min -1
NEW & NOTEWORTHY 72 73
The governing bodies for international apnea competition, the Association Internationale pour le 74
Développment de l'Apnée and La Confédération Mondaile des Activités Subaquatiques have 75
banned the use of beta-blockers based on anecdotal reports that they improve apnea duration. 76
Using a randomized placebo controlled trial we are the first to empirically confirm that beta-77 blockade improves apnea duration. This improvement in apnea duration coincided with a 78 reduced myocardial oxygen consumption.
INTRODUCTION: 80
Voluntary apnea elicits an integrative circulatory and neural response to maintain 81 adequate perfusion of vital organs (e.g. the brain), while simultaneously reducing both flow to 82 non-vital organs (e.g. skin and skeletal muscle) and total body oxygen consumption (9, 10, 20) . The precise mechanism(s) for apnea breakpoint remain poorly understood (24), but in the 98 motivated and elite breath hold diver are likely related in part to chemoreflex stress (3, 4) and a 99 critical oxygen level required to maintain consciousness (4, 31). Additional mechanisms have 100 been theorized to contribute to breakpoint in the untrained breath holder such as diaphragmatic 101 afference (24), however, how this translates to the motivated and elite breath holder is unknown.
104
Beta (β) adrenoreceptor antagonists (β-blockers) have been commonly used in elite apnea 105 competitions due to anecdotal reports of improved maximal apnea duration (personal 106 correspondence, Croatian National Apnea Coach). As a result, the Association Internationale 107 pour le Développment de l'Apnée (AIDA; http://www.aidainternational.org) and La 108
Confédération Mondaile des Activités Subaquatiques (CMAS; http://www.cmas.org) prohibit the 109 use of β-blockers in and out of competition. Given that recent work in elite apnea divers supports 110 the presence of a critical oxygen tension as a major contributor to apnea break point (4), the 111 present theory is that β-blockade improves maximal apnea duration via myocardial oxygen 112
sparing, yet there are no published data demonstrating this effect. In the first randomized and 113 placebo-controlled study of its kind, we determined the effects of β 1 -blockade on maximal apnea 114 duration and the circulatory parameters that are characteristic of extreme apnea. It was 115 hypothesized that β 1 -blockade would prolong apnea duration, owing to a reduced heart rate 116 throughout the apnea and a consequently reduced rate of myocardial oxygen consumption 117 (MVO 2 ). We further reasoned that the effects of β 1 -blockade would be reflected in the cerebral 118 vasculature through a lower CBF during baseline and end apnea compared to the placebo control 119 due to a reduced CO and MAP. 120
121

METHODS: 122 123
Subjects 124
Elite breath hold divers (n=9; 1 female) were recruited from the National Croatian Apnea 126 team to participate in this study. The divers were 29±9 years old, weighed 80±13Kg, and were 127 184±8cm tall (body mass index = 23.5±2.6). Personal record static apnea time was on average 128 394 seconds (range: 296-496), while divers had a mean of 4 years (range: 2-11) of experience in 129 competitive apnea training and an FVC of 6.9L (range: 5.0-7.8). Following written informed 130 consent, divers visited the laboratory on one occasion for the experimental session. Subjects 131 arrived at either 8am or 12pm having abstained from alcohol, caffeine, and exercise for 24 hours 132 prior to arrival. All subjects were free from any cardiovascular, respiratory, and cerebrovascular 133 disease at the time of study as assessed by a screening questionnaire and spirometry. used to measure beat-by-beat blood pressure and estimate cardiac output (CO), stroke volume 174 (SV), and total peripheral resistance (TPR), while standard three-lead electrocardiogram (ECG) 175 was used to measure heart rate. Peripheral oxyhemoglobin saturation (SpO 2 ) was measured 176 during baseline and throughout the apneas (Poet II, Criticare, USA). The IBM onset was 177 recorded in real time during the apnea by the apnea coach and verified from a chest 178 plethysmography belt. All data were interfaced with LabChart (version 7, ADInstruments) on a 179 laboratory computer were stored for offline analysis. angle were standardized within subject and between the esmolol and placebo conditions. An 227 angle correction of 60° was used for all subjects, while the velocity sample volume was placed in 228 the center of the vessel and adjusted to span across the entire luminal diameter. Baseline 229 recordings were made in all subjects (n=9); however, the sample size for VA measures 230 throughout an entire breath hold was reduced (n=6) due to strict exclusion criteria such as 231 obvious angle changes. 232
Ultrasound images of the extra-cranial vessels were recorded as video files at 30Hz and 233 stored for offline analysis. Concurrent values for arterial diameter and peak blood velocity were 234 acquired at 30Hz, using customized edge detection software designed to mitigate observer bias 235 and esmolol conditions at 10% relative increments in apnea duration using a two-way repeated 288 measures ANOVA (factors: esmolol & apnea duration). When significant F-ratios were detected, 289 post-hoc comparisons were made using Tukey's HSD. End apnea variables (final 30sec) in the 290 placebo and esmolol trials were compared using two-tailed paired t-tests (Table 1) Values and statistical output for HR, MAP, SV, CO, and TPR during each relative time 308 point throughout apnea are presented in Figure 2 . During the initial phase of apnea HR was 309 elevated in both placebo and esmolol trials, while esmolol reduced HR compared to placebo at 310 10-30% of apnea duration. In both trials MAP was elevated from baseline. Throughout apnea, 311 SV and CO were reduced from baseline, and lower (main effect: both P<0.01) during the 312 esmolol compared to placebo trial from 40% to max apnea and 20% to max apnea, respectively. 313
End apnea (final 30 seconds; Table 1 ) HR and MAP were not different between esmolol and 314 placebo, while SV and CO were reduced by 15% and 18% in the esmolol trial, respectively; 315 however, the difference in CO did not reach statistical significance (P=0.06). Esmolol increased 316 TPR (main effect: P=0.04) compared to placebo, while within condition TPR was elevated above 317 baseline from 20-100% of apnea duration. 318
There was a main effect of esmolol on MVO 2 (P<0.01; Figure 3) , which was lower in the 319 esmolol trial. In both trials MVO 2 was elevated from baseline at 30%, 40%, and 90%. There was 320 a 16.2±4.2% reduction in MVO 2 across all stages (range: 8.0-21.6%) in the esmolol trial. 321
However, there was no difference in the cumulative myocardial oxygen consumption between 322 the placebo (76.3±19.9mL) and esmolol (70.2±21.7 mL) trials (P=0.27; Figure 3B ) due to the 323 prolonged duration of the esmolol apnea. 324
325
Cerebral Blood Flow 326 327
Measures of Q ICA , Q VA , gCBF, MCAv and PCAv were not different between placebo and 328 esmolol at baseline (Table 2) . At the end of apnea (final 30 seconds) the sample size for gCBFand Q VA were reduced to six participants. In these six participants, gCBF was lower at the end of 330 apnea during the esmolol trial compared to placebo (Table 2) . 331
332
DISCUSSION 333 334
The primary findings of this study are: 1) β 1 -blockade with esmolol improves maximal 335 apnea duration in elite breath hold divers by ~10%, 2) esmolol reduces MVO 2 at each time point 336 throughout maximal apnea by ~16%, while the cumulative myocardial oxygen consumption was 337 unaltered, 3) there are marked changes in the hemodynamic response (TPR & CO) to apnea 338 between esmolol and placebo trials, and 4) end apnea SpO 2 was not different despite the 339 prolonged apnea in the esmolol trial. Collectively, these data support the hypothesis that apnea 340 breakpoint is influenced by β 1 -blockade but ultimately governed by a critical oxygen tension. 
Mechanisms Governing Apnea Termination 372
The physiological apnea breakpoint (i.e., cessation of breathhold) in untrained breath 374 holders, which is observed as IBM onset in elite breath hold divers, is governed largely by 375 chemoreceptor afferents (6, 11). Breskovic et al., 2012 suggested that IBM onset is related 376 predominantly to a PaCO 2 threshold level of 6.5 ± 0.5 kPa ( 48.8mmHg). A similar PaCO 2 377 threshold for IBM onset has been reported in most (1, 21) but not all (4) earlier studies, 378 highlighting the importance of PaCO 2 in initiating the physiological breakpoint. Nevertheless, 379 the prevailing oxygen tension will impact the level of PaCO 2 at which IBM onset occurs (6). 380
These chemoreflex interactions, along with a modulatory role from lung afferents (reviewed in: 381 (24)) indicate that it is the integration of signals (i.e., peripheral and central chemo-afference) 382 that collectively govern the physiological breakpoint. 383
Concurrent decreases in O 2 depletion and CO 2 production, both a consequence of a 384 reduced metabolism, will act to attenuate arterial blood gas changes and hence chemoreflex 385 stimulation. Indeed, our findings show that IBM onset was delayed by ~32 seconds, but 386 nevertheless occurred at the same level of SpO 2 between trials (Placebo = 97.8±1.3%; Esmolol = 387 96.4±2.2%). Under the assumption that the respiratory exchange ratio was unaltered between 388 trials, a similar reduction in SpO 2 signifies that metabolic CO 2 production likely did not differ 389 and was also similar between trials at IBM onset. Therefore, despite the delayed IBM onset with 390 esmolol treatment, IBMs likely occurred at the same level of chemoreflex stress with no 391 influence from altered chemosensitivity (13) or CO 2 washout in the brainstem (i.e., Q VA, an index 392 of brainstem flow, was similar between trials). Therefore, it is likely that the delay in reaching a 393 chemoreflex threshold was responsible for delayed IBM onset (or physiological breakpoint). In 394 contrast to the physiological breakpoint, the actual apnea termination in elite breath hold divers 395 appears to be only modestly affected by suppression of peripheral chemoreflex drive (4).
Typically it is accepted that man is incapable of sustaining a voluntary apnea to the point 397 of losing consciousness (27). However, many elite apnea divers are able to suppress their 398 ventilatory drive during an apnea to the loss of consciousness (unpublished observations). This 399 latter point is reflected in that AIDA includes loss of consciousness as a criterion for 400 disqualification during apnea competition. At this point, the apnea 'breakpoint' is potentially 401 governed to a large extent by a threshold oxygen tension to maintain cerebral functioning and, severe as previous study indicating the potential of a oxygen threshold for apnea termination (4), 409 the similar end apnea SpO 2 indicates some role of hypoxia in mediating apnea breakpoint in both 410 trials. Of note, data from our previous study (4) where concurrent SpO 2 (finger pulse-oximetry) 411
and SaO 2 (radial artery blood draw) measures were collected, indicate that SpO 2 overestimates 412 SaO 2 by a mean value of ~5%, and that this over estimation is largest below an SpO 2 of 70% 413 (Figure 4) . Therefore, it is likely the end apnea hypoxic stimulus was similar to our previous 414 studies in elite breath hold divers (4, 31). These data are similar to our previous findings in elite 415 breath hold divers of similar end apnea PaO 2 , despite moderate prolongation (but in some cases 416 reductions) in maximal apnea time following peripheral chemoreflex blunting with low dose 417 dopamine (4).
In the current study, centralization of blood volume and therefore a reduction of non-vital 419 organ perfusion but maintenance of vital organ oxygen delivery, in combination with myocardial 420 oxygen sparring, likely reduced both the hypoxic and acidotic stresses characteristic of extreme 421 apnea. Together, these factors likely underscore the increased apnea duration with esmolol. 422
423
Methodological Considerations 424 425
In the current study we have used RPP and echocardiographic assessment of left 426 ventricular mass to estimate left ventricular MVO 2 from the equation reported by Gobel et al., 427 1978 (12) . Although RPP has been shown as an excellent (r=0.85) correlate of MVO 2 during 428 exercise pre-and post-β-blockade (propranolol) (17), we acknowledge that this validation has 429 not been made during the specific conditions of prolonged apnea. Despite this, it is unlikely that 430 our estimates of RPP and MVO 2 would differ between conditions and discredit our findings. 431
Further, although we used comparable doses to other studies (16), we must acknowledge that we 432 did not assess the completeness of our β 1 -blockade. However, the presence of an incomplete 433 block would have lead to an underestimation of the magnitude by which esmolol impacts apnea 434
duration. 435
We used SpO 2 to quantify the hypoxic stimulus during prolonged breath hold during 436 placebo (saline) and esmolol infusion. As demonstrated in Figure 4 , SpO 2 over estimates SaO 2 437 substantially below a SaO 2 of ~70%. However, given the over estimation of SaO 2 , our data 438 should be interpreted as presenting similar end apnea hypoxic stress as previous investigations 439 by our group (4, 31). 440
CONCLUSION 442 443
This study contributes to the recent body of literature (4, 31) supporting the emerging 444 hypothesis that apnea breakpoint in elite breath hold divers is governed to a large extent by an 445 oxygen threshold for the maintenance of consciousness. Cardiac specific β 1 -blockade with 446 esmolol improved apnea duration in the current study and thus acts as an effective ergogenic aid 447 in apnea competition. The likely mechanisms by which esmolol increased apnea duration is 448 through increased centralization of blood flow (due to ↑TPR), maintenance of vital organ 449 perfusion, and a reduced MVO 2 . Together these two factors would contribute to improved total 450 body oxygen sparring and reduced metabolic CO 2 production. represented by open circles (○) and solid lines, while mean data is represented by filled squares 576 (■) and the dashed line. Overall there was a 32±25 second increase in apnea duration with 577 esmolol treatment. * denotes a significant difference in apnea duration (P<0.01). 578 579 Figure 2 . The hemodynamic response to maximal apnea during placebo and esmolol 580 infusion. Data are normalized within subjects to represent 10% increments in apnea duration.
581
Closed circle (•) represent data from the placebo trial. Open squares (□) represent data from the 582 esmolol trial. Data were analyzed using a two way repeated measures ANOVA with the factors 583 of apnea duration and esmolol treatment. * significant difference from baseline P<0.05; † main 584 effect of treatment P<0.05; ‡ interaction between apnea time and treatment. HR, heart rate; 585 MAP, mean arterial pressure; SV, stroke volume; CO, cardiac output; TPR, total peripheral 586 resistance. 587 588 demonstrates an over estimation of SaO 2 (radial blood draw) by SpO 2 (finger pulse-oximetry) at 599 the end of apnea in elite breath hold divers using data from our previous study (4). 
